Tejas Sankar

Dr. Tejas Sankar

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2013 in The Lancet Neurology
Verified
Journal Article
Closed access
NLNir Lipsman
Nir Lipsman
MSMichael L Schwartz
Michael L Schwartz
YHYuexi Huang
Yuexi Huang
LLLiesly Lee
Liesly Lee
TSTejas Sankar
Tejas Sankar
ALAndres M Lozano
Andres M Lozano

1 May 2015 in Brain Stimulation
Verified
Journal Article
Closed access
TSTejas Sankar
Tejas Sankar
MCM. Mallar Chakravarty
M. Mallar Chakravarty
ABAgustin Bescos
Agustin Bescos
MLMonica Lara
Monica Lara
TOToshiki Obuchi
Toshiki Obuchi
ALAndres M Lozano
Andres M Lozano

1 August 2013 in Current Opinion in Neurology
Verified
Journal Article
Closed access
SKSuneil K. Kalia
Suneil K. Kalia
TSTejas Sankar
Tejas Sankar
ALAndres M Lozano
Andres M Lozano
Deep brain stimulation (DBS) is now widely used in the treatment of Parkinson's disease, tremor, and dystonia. This review examines recent developments in the application of DBS to the management of movement disorders. In Parkinson's disease, recent work has demonstrated that early DBS may have a significant benefit on quality of life and motor symptoms while permitting a decrease in levodopa equivalent dosage. Thalamic DBS continues to be a well established target for the treatment of tremor, although recent work suggests that alternative targets such as the posterior subthalamic area may be similarly efficacious. The treatment of primary dystonia with DBS has been established in multiple recent trials, demonstrating prolonged symptomatic benefit. DBS is now an established symptomatic treatment modality for Parkinson's disease and other movement disorders. Future work will undoubtedly involve establishing new indications and targets in the treatment of movement disorders with further refinements to existing technology. Ultimately, these methods combined with biologically based therapies may catalyze a shift from symptomatic treatment to actually modifying the natural history of neurodegenerative diseases such as Parkinson's disease.

29 June 2009 in Cell Proliferation
Verified
Journal Article
Closed access
SES. E. Eikenberry
S. E. Eikenberry
TSTejas Sankar
Tejas Sankar
MPM. C. Preul
M. C. Preul
EKE. J. Kostelich
E. J. Kostelich
CTC. J. Thalhauser
C. J. Thalhauser
YKY. Kuang
Y. Kuang

1 February 2010 in Neurosurgery
Verified
Journal Article
Closed access
PDF file
TSTejas Sankar
Tejas Sankar
PDPeter M. Delaney
Peter M. Delaney
RRRobert W. Ryan
Robert W. Ryan
JEJennifer Eschbacher
Jennifer Eschbacher
MAMohammed Abdelwahab
Mohammed Abdelwahab
MPMark C. Preul
Mark C. Preul
INTRODUCTION. Recent developments in optical science and image processing have miniaturized the components required for confocal microscopy. Clinical co

25 January 2018 in Journal of Neurology, Neurosurgery & Psychiatry
Verified
Journal Article
Closed access
PDF file
ABAusaf A Bari
Ausaf A Bari
CMCharles B Mikell
Charles B Mikell
AAAviva Abosch
Aviva Abosch
SBSharona Ben-Haim
Sharona Ben-Haim
RBRobert J Buchanan
Robert J Buchanan
Sameer A. ShethSameer A. Sheth
Sameer A. Sheth
Objective Refractory psychiatric disease is a major cause of morbidity and mortality worldwide, and there is a great need for new treatments. In the last decade, investigators piloted novel deep brain stimulation (DBS)-based therapies for depression and obsessive–compulsive disorder (OCD). Results from recent pivotal trials of these therapies, however, did not demonstrate the degree of efficacy expected from previous smaller trials. To discuss next steps, neurosurgeons, neurologists, psychiatrists and representatives from industry convened a workshop sponsored by the American Society for Stereotactic and Functional Neurosurgery in Chicago, Illinois, in June of 2016. Design Here we summarise the proceedings of the workshop. Participants discussed a number of issues of importance to the community. First, we discussed how to interpret results from the recent pivotal trials of DBS for OCD and depression. We then reviewed what can be learnt from lesions and closed-loop neurostimulation. Subsequently, representatives from the National Institutes of Health, the Food and Drug Administration and industry discussed their views on neuromodulation for psychiatric disorders. In particular, these third parties discussed their criteria for moving forward with new trials. Finally, we discussed the best way of confirming safety and efficacy of these therapies, including registries and clinical trial design. We close by discussing next steps in the journey to new neuromodulatory therapies for these devastating illnesses. Conclusion Interest and motivation remain strong for deep brain stimulation for psychiatric disease. Progress will require coordinated efforts by all stakeholders.